Skip to main content
AbClon Inc. logo

AbClon Inc. — Investor Relations & Filings

Ticker · 174900 ISIN · KR7174900001 KO Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2019-11-13 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 174900

About AbClon Inc.

https://www.abclon.com/en/

AbClon Inc. is a clinical-stage company focused on the research and development of antibody-based therapeutics. The company leverages three core proprietary platforms. The CAR-T platform develops personalized cell therapies for cancer patients by engineering a patient's own immune cells to target and destroy cancer cells, with a focus on blood cancers. The NEST (Novel Epitope Screening Technology) platform is designed to discover antibodies that target unique, previously unaddressed sites on disease proteins, enabling novel therapeutic effects. The AffiMab platform facilitates the development of bispecific antibodies that can simultaneously engage two different disease targets, aiming to maximize therapeutic efficacy in refractory diseases.

Recent filings

Filing Released Lang Actions
분기보고서 (2019.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for the company '앱클론(주)' (AbClon Inc.) covering the period from 2019-01-01 to 2019-09-30. It contains detailed financial statements, business descriptions, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2019
2019-11-13 Korean
기타경영사항(특허권취득)(자율공시)(HER2에 특이적으로 결합하는 항체)
Regulatory Filings Classification · 95% confidence The document is a regulatory disclosure from AbClon regarding the acquisition of a patent for a HER2-binding antibody. It is filed as a 'voluntary disclosure' (자율공시) under the category of 'Other Management Matters' (기타 경영사항). Since it does not fit into specific categories like financial reports, board changes, or share transactions, it falls under the general regulatory filing category.
2019-09-25 Korean
기타경영사항(특허권취득)(자율공시)(VEGFR2에 특이적으로 결합하는 항체 (ANTIBODIES CAPABLE OF BINDING SPECIFICALLY TO VEGFR2))
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent (특허권 취득) by the company AbClon. It details the patent name, content, and strategic utilization plans. Since this is a regulatory announcement regarding a specific corporate event (patent acquisition) that does not fit into financial reporting, dividend, or management change categories, it is classified as a general regulatory filing.
2019-09-24 Korean
기타경영사항(특허권취득)(자율공시)(시스테인으로 변형된 항체 및 이를 이용한 부위-특이적 접합)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) regarding the acquisition of a patent (특허권 취득) by the company AbClon. It details the patent name, content, and its strategic application in the company's CAR-T platform. Since this is a specific corporate announcement regarding a business development (patent acquisition) that does not fit into financial reporting, governance, or shareholder meeting categories, it falls under the general regulatory filing category.
2019-09-18 Korean
기타경영사항(특허권취득)(자율공시)(단백질의 순도 및 항원에 대한 친화성이 향상된 폴리펩티드, 이의 항체 또는 항원 결합 단편과의 복합체, 및 이들의 제조방법)
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure (자율공시) by AbClon regarding the acquisition of a patent for a polypeptide with improved protein purity and antigen affinity. It details the patent name, content, and its application in the company's drug development pipeline (AM201). Since this is a regulatory disclosure of a specific corporate event (patent acquisition) that does not fit into financial reporting, dividend, or management change categories, it is classified as a general regulatory filing.
2019-08-20 Korean
반기보고서 (2019.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for the company '앱클론(주)' (AbClon Inc.) covering the period from 2019-01-01 to 2019-06-30. It contains detailed financial statements, business descriptions, and management analysis, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2019
2019-08-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.